David has been a leader in the medical cannabis field since 2009 when he led the development of the world’s first cannabis withdrawal measurement scale, providing a high quality measurement tool for clinicians and researchers to monitor adverse effects during medication titration. This work helped understand the clinical significance of cannabinoid withdrawal, leading to its inclusion in the DSM-5 for the first time. David led Australia’s first ever-clinical trial administering a cannabis-based medicine to humans, using Sativex as a Cannabinoid Replacement Therapy. David is currently a Director in the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney, setting strategic clinical direction to encourage and support research and community awareness for cannabis based medicines.